Enzyme (Serine protease), Type II transmembrane serine protease (TTSP)
01
Overview
Transmembrane protease serine 11D (TMPRSS11D) is a cell-surface, single-pass transmembrane serine protease most highly expressed in respiratory epithelium and other epithelial tissues. It belongs to the HAT/DESC subfamily of TTSPs and is active following autocleavage at its zymogen activation motif. TMPRSS11D is implicated in host defense, processing of proteins at epithelial barriers, and facilitating the entry of respiratory viruses such as SARS-CoV-2 and Influenza A/B into host cells. In cancer, TMPRSS11D expression promotes proliferation, migration, invasion, and epithelial–mesenchymal transition, correlating with poor prognosis and high-grade disease in several carcinomas. As a therapeutic target, TMPRSS11D is a focus for antiviral and anti-cancer agents, but inhibitor development is challenged by substrate specificity and protease redundancy across TTSPs.
Inhibition of serine protease activity (blocking viral entry, tissue remodeling, and cancer progression by targeting substrate recognition or autocleavage site)
03
Biological functions
Host defense (can cleave and process proteins involved in innate immunity)Facilitation of viral entry (cleaves viral proteins, notably facilitating SARS-CoV-2 and Influenza virus cell entry)Extracellular matrix proteolysis (involved in tissue remodeling and cell migration)Regulation of epithelial biology (localizes to cilia and cell surface in respiratory and other epithelia)Cell proliferation, migration, and invasion (in cancer progression and epithelial–mesenchymal transition)
04
Disease associations
Infection (SARS-CoV-2, Influenza A/B, other respiratory viruses)Cancer (cervical cancer, non-small cell lung cancer, squamous cell carcinogenesis, and others)Metastasis (by promoting epithelial–mesenchymal transition and extracellular matrix degradation)Other (potential roles in host defense and tissue homeostasis)
05
Safety considerations
Potential off-target effects due to broad substrate specificity among serine proteases in the TTSP familyPossible conversion/inactivation of protease inhibitors (e.g., rapid cleavage of nafamostat)Disruption of normal epithelial homeostasis and host defense if inhibited chronically
06
Interacting drugs
Nafamostat mesylate (broad serine protease inhibitor evaluated in COVID-19 context; rapidly cleaved by TMPRSS11D, limiting efficacy)
1 more in the full profile.
07
Biomarkers
High TMPRSS11D protein expression (marker for poor prognosis and high tumor stage in NSCLC; marker for cell invasion and epithelial–mesenchymal transition in cancer tissues)
Beyond the preview
Go deeper on Transmembrane protease serine 11D (TMPRSS11D).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transmembrane protease serine 11D (TMPRSS11D).